WallStSmart

S&P Global Inc (SPGI)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

S&P Global Inc generates 5824% more annual revenue ($15.34B vs $258.90M). SPGI leads profitability with a 29.1% profit margin vs -15.5%. SPGI earns a higher WallStSmart Score of 67/100 (B-).

SPGI

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.97

ZEPP

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SPGIUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$687.02

Current Price

$408.48

$278.54 discount

UndervaluedFair: $687.02Overvalued

Intrinsic value data unavailable for ZEPP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SPGI5 strengths · Avg: 8.8/10
Operating MarginProfitability
38.3%10/10

Strong operational efficiency at 38.3%

Market CapQuality
$124.51B9/10

Large-cap with strong market position

Profit MarginProfitability
29.1%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
32.0%8/10

Earnings expanding 32.0% YoY

Free Cash FlowQuality
$1.70B8/10

Generating 1.7B in free cash flow

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SPGI2 concerns · Avg: 4.0/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$216.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SPGI

The strongest argument for SPGI centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 29.1% and operating margin at 38.3%.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SPGI

The primary concerns for SPGI are P/E Ratio, Altman Z-Score.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SPGI profiles as a mature stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SPGI scores higher overall (67/100 vs 43/100), backed by strong 29.1% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

S&P Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

S&P Global Inc. is an American publicly traded corporation headquartered in Manhattan, New York City. Its primary areas of business are financial information and analytics.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?